Not IDEAL: Protagonist sinks as high dose of oral Entyvio rival fails in ulcerative colitis

Protagonist Therapeutics has failed to persuade investors of its take on a phase 2 ulcerative colitis trial. While the biotech made the case that the low dose was a big success, investors picked out the failure of the high dose as the key finding and sent the stock spiraling downward.